Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page revision was updated from v3.6.0 to v3.6.2, indicating a maintenance update to the ClinicalTrials.gov record. This reflects behind-the-scenes fixes or tweaks and does not alter the study details presented to users.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe study record now indicates termination due to poor accrual and includes the note 'No longer looking for participants.' Navigation/help items were added (How to Read a Study Record, Common Questions, How to Join a Study), and the revision label was updated to v3.6.0 with a heading adjustment for Intervention/Treatment.SummaryDifference0.6%

- Check24 days agoChange DetectedFooter revision updated from v3.5.4 to v3.5.5, indicating a new version of the page. No substantive content, including the study details or eligibility criteria, was changed.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4, signaling a new release of the page content.SummaryDifference0.1%

- Check67 days agoChange DetectedThe page’s revision label was updated from v3.5.2 to v3.5.3, indicating a version/release change to the ClinicalTrials.gov site interface rather than a modification to the study content.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.